What are the costs of glenohumeral osteoarthritis in the year prior to a total shoulder arthroplasty (TSA)?

Abstract

ABSTRACTObjectives: To identify patterns of health-care utilization and costs associated with management of glenohumeral osteoarthritis in the year prior to undergoing an anatomic total shoulder arthroplasty (ATSA).Methods: The PearlDiver Humana database, an administrative database of Medicare Advantage (MA) and Commercial insurance beneficiaries was queried for active records of patients undergoing a primary ATSA from the fourth quarter of 2010–2015. Pre-operative health-care utilization was categorized as 1) Procedures & Anesthesia, 2) Office visits, 3) Radiology, 4) Injections – a) Steroid injections and b) Hyaluronic Acid (HA) injections, 5) Physical Therapy, 6) Non-opioid pain medications and 7) Opioids. Overall costs/reimbursement and Per-patient average reimbursements (PPARs) were calculated for each category.Results: A total of 3,920 patients (MA = 3,691; Commercial = 229) undergoing primary ATSA were retrieved. Based on defined categories, the total costs prior to ATSA were $368,137 and $2,812,617 for Commercial and MA beneficiaries, respectively. Overall 1-year PPAR for each category was as follows: Procedures & Anesthesia (MA = $1765; Commercial = $5333), Office visits (MA = $441; Commercial = $396); Radiology (MA = $253; Commercial = $558), Injections (MA = $117, Commercial = $173), Physical therapy (MA = $473; Commercial = $372), Non-opioid pain meds (MA = $49; Commercial = $147) and Opioids (MA = $26; Commercial = $49). The highest utilization was seen in the three months prior to ATSA with 42–81% of overall PPAR being accounted for various categories.Conclusion: A high utilization of all health-care resource categories was noted within three months prior to surgery. Providers should consider judicious use of such interventions, particularly in patients which ultimately require surgery in a short frame of time, to reduce the costs associated with the overall episode of care.